Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v2.3.0.15
Consolidated Statements of Operations (Unaudited) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Sep. 30, 2010
Income Statement [Abstract]        
Sales $ 3,930,503 $ 4,515,222 $ 8,937,818 $ 11,133,223
Cost of sales (2,144,952) (2,400,005) (4,668,316) (5,555,191)
Gross profit 1,785,551 2,115,217 4,269,502 5,578,032
Operating Expenses:        
General and adminstrative expenses 3,792,480 1,684,248 6,884,039 4,461,004
Depreciation expense 205,352 87,867 372,002 249,473
Research and development expenses 4,011 54,837 119,167 149,497
Total Operating Expenses 4,001,843 1,826,952 7,375,208 4,859,974
Income (Loss) from operations (2,216,292) 288,265 (3,105,706) 718,058
Interest expense (283,411) (123,415) (505,606) (323,142)
Income (Loss) before provision for income taxes (2,499,703) 164,850 (3,611,312) 394,916
(Provision) benefit for income taxes   92,000    
Net income (loss) including noncontrolling interest (2,499,703) 256,850 (3,611,312) 394,916
Less: Net income (loss) attributable to noncontrolling interest       (696)
Net income (loss) attributable to Biozone $ (2,499,703) $ 256,850 $ (3,611,312) $ 395,612
Income (Loss) per common share $ (0.04) $ 0.01 $ (0.07) $ 0.01
Basic and diluted weighted average common share outstanding 67,492,714 37,698,000 49,112,016 37,698,000